Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) evidence summary new medicines (ESNM65) -

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) evidence summary new medicines (ESNM65)
Information type: Evidence summaries
Source: National Institute for Health
Specialities: Diabetes
Summary
Insulin glargine 300units/ml (Toujeo) received a European marketing authorisation in April 2015. It was launched in the UK in August 2015.This evidence summary discusses the best available evidence for clinical effectiveness and safety.
UKMi comment
This can be read in conjunction with the previous evidence summary ESNM62 on the use of this product for Type 1 diabetes. UKMi have also produced an in use product safety assessment for this medicine.
Related links: UKMi Assessment NICE ESNM62